Lancet Rheumatology最新文献

{"title":"Thank you to The Lancet Rheumatology's peer reviewers in 2024","authors":"The Lancet Rheumatology Editors","doi":"10.1016/S2665-9913(25)00038-4","DOIUrl":"10.1016/S2665-9913(25)00038-4","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 3","pages":"Pages e155-e158"},"PeriodicalIF":15.0,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm","authors":"Prof Walter P Maksymowych MD , Prof Robert G W Lambert MD , Rebecca J Bolce Ms , Natalia Bello MD , Baojin Zhu PhD , Jeffrey R Lisse MD , Prof Mikkel Østergaard MD","doi":"10.1016/S2665-9913(24)00312-6","DOIUrl":"10.1016/S2665-9913(24)00312-6","url":null,"abstract":"<div><h3>Background</h3><div>The effect of biological disease-modifying antirheumatic drugs (DMARDs) on sacroiliac joint lesions over 52 weeks in biological DMARD-naive patients with radiographic axial spondyloarthritis is unknown. This post-hoc analysis evaluated the effect of ixekizumab and adalimumab versus placebo on structural lesions in sacroiliac joints assessed by MRI in patients naive to biological DMARDs with radiographic axial spondyloarthritis from the COAST-V study.</div></div><div><h3>Methods</h3><div>COAST-V was a phase 3, multicentre, randomised, double-blind, placebo-controlled trial with an active reference arm done over 52 weeks at 84 sites in 12 countries. Eligible patients were adults (aged ≥18 years) naive to biological DMARDs with active radiographic axial spondyloarthritis, radiographic evidence of sacroiliitis, and an inadequate response or intolerance to non-steroidal anti-inflammatory drugs. Patients were randomly assigned (1:1:1:1) to 80 mg ixekizumab every 2 weeks (Q2W) or every 4 weeks (Q4W), 40 mg adalimumab Q2W, or placebo. At week 16, patients receiving placebo or adalimumab were randomly assigned (1:1) again to ixekizumab Q2W or ixekizumab Q4W. Post-hoc analyses of patients with MRI available at baseline, 16 weeks, and 52 weeks are reported. MRIs were scored using the Spondyloarthritis Research Consortium of Canada sacroiliac joint structural scores for erosion, backfill, fat lesions, and ankylosis. ANCOVA was used for treatment comparisons in observed cases adjusting for baseline values, bone marrow oedema, and stratification factors. Subgroup analyses by sex, HLA-B27, and baseline bone marrow oedema were done.</div></div><div><h3>Findings</h3><div>Between June 20, 2016, and Aug 22, 2017, 341 patients were enrolled in the COAST-V study. MRI scans were available for 325 (95%) of 341 patients at baseline and week 16, and for 301 (88%) patients at week 52. 264 (81%) of 325 patients were male and 61 (19%) were female, and the mean age was 41·5 years (SD 11·6). At week 16, erosion significantly decreased versus placebo in the ixekizumab Q2W group (least squares mean –0·91 [SE 0·19] <em>vs</em> 0·10 [0·18]; p<0·0001) and the ixekizumab Q4W group (–0·57 [SE 0·19]; p=0·0086]); the effect of adalimumab was similar. Backfill significantly increased from baseline to week 16 in ixekizumab Q2W versus placebo (0·52 [0·12] <em>vs</em> 0·04 [0·12]; p=0·0042). At week 16, decreases in erosion differed significantly between the placebo group and ixekizumab Q2W or Q4W groups, and differences were seen by sex, HLA-B27 status, and baseline bone marrow oedema score. At week 52, at both ixekizumab doses, further changes were observed in erosion and backfill, which were greatest with continuous ixekizumab Q2W (mean erosion –1·50 [SD 2·70], mean backfill 0·76 [SD 2·09]). A decrease in erosion was also noted in patients switching from adalimumab to ixekizumab at week 16. COAST-V was registered with <span><span>ClinicalTrials.gov</span","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 5","pages":"Pages e314-e322"},"PeriodicalIF":15.0,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological disease-modification in axial spondyloarthritis: insights from MRI","authors":"Torsten Diekhoff , Sevtap Tugce Ulas","doi":"10.1016/S2665-9913(24)00352-7","DOIUrl":"10.1016/S2665-9913(24)00352-7","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 5","pages":"Pages e304-e305"},"PeriodicalIF":15.0,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine and cardiovascular protection in gout: unresolved questions – Authors' reply","authors":"Edoardo Cipolletta , Laila J Tata , Abhishek Abhishek","doi":"10.1016/S2665-9913(25)00025-6","DOIUrl":"10.1016/S2665-9913(25)00025-6","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 3","pages":"Page e161"},"PeriodicalIF":15.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine and cardiovascular protection in gout: unresolved questions","authors":"Masanari Kuwabara , Naoyuki Ohtani , Ichiro Hisatome","doi":"10.1016/S2665-9913(25)00024-4","DOIUrl":"10.1016/S2665-9913(25)00024-4","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 3","pages":"Pages e160-e161"},"PeriodicalIF":15.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis","authors":"Sijia Liu , Jialao Ma","doi":"10.1016/S2665-9913(25)00028-1","DOIUrl":"10.1016/S2665-9913(25)00028-1","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 3","pages":"Page e159"},"PeriodicalIF":15.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial","authors":"Michelle Hall PhD ,&nbsp;Kim Allison PhD ,&nbsp;Gabrielle Knox BSc ,&nbsp;Fiona McManus MBiostat ,&nbsp;Prof Rana S Hinman PhD ,&nbsp;Prof Kim L Bennell PhD ,&nbsp;Libby Spiers BSc ,&nbsp;Anurika P De Silva PhD ,&nbsp;David M Klyne PhD ,&nbsp;Melanie L Plinsinga PhD ,&nbsp;Ricardo J S Costa PhD ,&nbsp;Nicholas J Murphy PhD ,&nbsp;Wen Wu PhD ,&nbsp;Prof Fiona L Dobson PhD","doi":"10.1016/S2665-9913(24)00373-4","DOIUrl":"10.1016/S2665-9913(24)00373-4","url":null,"abstract":"<div><h3>Background</h3><div>Exercise is recommended for hip osteoarthritis, but the most effective programmes for management of symptoms are unknown. We aimed to investigate whether adding aerobic physical activity to resistance exercise would improve hip pain and function more than resistance exercise alone in individuals with hip osteoarthritis.</div></div><div><h3>Methods</h3><div>PHOENIX was a randomised comparative effectiveness trial done in Melbourne, Australia. We recruited people with a clinical diagnosis of symptomatic hip osteoarthritis. Participants were randomly assigned (1:1, by use of a web-based system) to aerobic physical activity and resistance exercise or resistance exercise only. Both groups received a home exercise programme and nine consultations with a physiotherapist over 3 months. The co-primary outcomes were change in hip pain severity (numerical rating scale [NRS] 0–10, with higher scores indicating worse outcomes) and function (Western Ontario and McMaster Osteoarthritis Index [WOMAC]; scale 0–68, with higher scores indicating worse outcomes) at 3 months. Analyses were done in the intention-to-treat population. People with lived experience of hip osteoarthritis were involved in the design of the study. This trial is registered with the Australian New Zealand Clinical Trial Registry (ACTRN 12619001297112), and is complete.</div></div><div><h3>Findings</h3><div>Between Oct 15, 2019, and Sept 13, 2022, 196 participants (134 [68%] women and 62 [32%] men) were randomly assigned to aerobic physical activity and resistance exercise (n=97) or resistance exercise only (n=99). At 3 months, aerobic physical activity and resistance exercise was not more effective in improving hip pain severity (mean difference 0·3 [95% CI –0·3 to 0·8; p=0·36]) or function (mean difference –0·9 [95% CI –3·6 to 1·8; p=0·51]) compared with resistance exercise alone, with both showing a mean improvement in pain (2·4 [SD 1·9] with aerobic physical activity and resistance exercise <em>vs</em> 2·2 [2·1] with resistance exercise only) and function (7·0 [10·4] with aerobic physical activity and resistance exercise <em>vs</em> 8·9 [10·8] resistance exercise only). There were 24 related adverse events with aerobic physical activity and resistance exercise, and 31 with resistance exercise only, none of which were serious.</div></div><div><h3>Interpretation</h3><div>Despite improvement in pain and function in both groups, adding moderate-intensity aerobic physical activity to resistance exercise did not lead to superior outcomes. Future work could consider higher intensity interval training before concluding no symptomatic benefit of adding aerobic exercise or physical activity to resistance exercise.</div></div><div><h3>Funding</h3><div>National Health and Medical Research Council, Australia.</div></div>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 5","pages":"Pages e343-e354"},"PeriodicalIF":15.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing evidence gaps in exercise for hip osteoarthritis","authors":"Troels Kjeldsen ,&nbsp;Inger Mechlenburg","doi":"10.1016/S2665-9913(24)00378-3","DOIUrl":"10.1016/S2665-9913(24)00378-3","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 5","pages":"Pages e308-e310"},"PeriodicalIF":15.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis – Authors' reply","authors":"Mark D Russell ,&nbsp;Mark Gibson ,&nbsp;Benjamin Zuckerman ,&nbsp;Kanta Kumar ,&nbsp;Shirish Dubey ,&nbsp;Maryam A Adas ,&nbsp;Edward Alveyn ,&nbsp;Samir Patel ,&nbsp;Zijing Yang ,&nbsp;Katie Bechman ,&nbsp;Elizabeth Price ,&nbsp;Sarah Gallagher ,&nbsp;Andrew P Cope ,&nbsp;Sam Norton ,&nbsp;James B Galloway","doi":"10.1016/S2665-9913(25)00029-3","DOIUrl":"10.1016/S2665-9913(25)00029-3","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 3","pages":"Pages e159-e160"},"PeriodicalIF":15.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival in patients with rheumatoid arthritis and recently diagnosed early-stage colorectal, lung, or prostate cancer receiving tumour necrosis factor inhibitors: a retrospective cohort study","authors":"Juan I Ruiz MD ,&nbsp;Xiudong Lei PhD ,&nbsp;Prof Sharon H Giordano MD ,&nbsp;Hui Zhao PhD ,&nbsp;Suja S Rajan PhD ,&nbsp;Heather Lin PhD ,&nbsp;Prof Maria E Suarez-Almazor MD","doi":"10.1016/S2665-9913(24)00379-5","DOIUrl":"10.1016/S2665-9913(24)00379-5","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Tumor necrosis factor (TNF) inhibitors could impair tumoural immunity in patients with rheumatoid arthritis and cancer. We aimed to investigate the association between survival and TNF inhibitor treatment during the first 3 years after a diagnosis of colorectal, lung, or prostate cancer in patients with rheumatoid arthritis.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;In this cohort study, we conducted a secondary data analysis of the Surveillance, Epidemiology, and End Results Medicare-linked dataset. We included patients aged 66 years and older with rheumatoid arthritis diagnosed with colorectal, lung, or prostate cancer between Jan 1, 2008, and Dec 31, 2019, using ICD-O-3 site and histology codes. We limited the cohort to patients who had early-stage cancer (localised or regional). We only included patients who received TNF inhibitors, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), or no DMARDs in the first year after cancer diagnosis. The primary outcomes were 5-year overall survival and cancer-specific survival. Exposures were use of TNF inhibitors, conventional synthetic DMARDs, or no DMARDs within 3 years after cancer diagnosis. Other covariates included demographics and comorbidities. We conducted landmark analyses at years 1, 2, and 3, with Cox regression adjusted by propensity scores. People with lived experience of rheumatoid arthritis and cancer were not involved in the design or conduct of this study.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;We identified three cohorts of patients diagnosed with early-stage colorectal cancer (n=514), lung cancer (n=864), or prostate cancer (n=603) between Jan 1, 2008, and Dec 31, 2019. In the colorectal cancer cohort, the mean age was 76·1 years (SD 6·4), 385 (75%) of 514 patients were female, 129 (25%) were male, and 405 (79%) were White and non-Hispanic. In the lung cancer cohort, the mean age was 74·8 years (SD 5·9), 632 (73%) of 864 patients were female, 232 (27%) were male, and 743 (86%) were White and non-Hispanic. In the prostate cancer cohort, the mean age was 73·1 years (SD 5·1), 603 (100%) patients were male, and 492 (82%) were White and non-Hispanic. 80 (16%) of 514 patients with colorectal cancer, 102 (12%) of 864 patients with lung cancer, and 120 (20%) of 603 patients with prostate cancer received TNF inhibitors with or without conventional synthetic DMARDs at any time during the first year after cancer diagnosis. No significant deleterious association was observed for overall survival or cancer-specific survival for any of the cancers at any of the three landmark points. Hazard ratios and 95% CIs for overall survival for year 1 comparing TNF inhibitors with conventional synthetic DMARDs in the three cohorts were 0·72 (0·43–1·21) for colorectal cancer, 0·70 (0·49–1·00) for lung cancer, and 0·80 (0·44–1·44) for prostate cancer. Patients who received glucocorticoids in the first year had significantly worse overall survival and cancer-specific su","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 5","pages":"Pages e333-e342"},"PeriodicalIF":15.0,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}